10-Q: Air Industries Group Faces Going Concern Doubt Amid Debt Maturities

Sentiment:

Quarterly Report 14 November 2025 4:02 PM

Air Industries Group reported a reduced net loss in Q3 2025 but faces substantial doubt about its ability to continue as a going concern due to upcoming debt maturities and covenant defaults.

Delay expectedRevenue acceleration from recent contract awards and backlog is expected to be delayed until early 2026 due to extended lead times for raw material procurement and the complexity of manufacturing processes.

Capital raiseThe company generated gross proceeds of $4,869,000 through an At The Market (ATM) Offering during the nine months ended September 30, 2025, by selling 1,213,593 shares of common stock.Approximately $3,930,000 of the ATM proceeds is restricted for the benefit of the Current Credit Facility lender as additional security.The company has temporarily paused all equity raising activity while evaluating the most effective capital structure going forward.Management states that additional issuances of equity or convertible debt securities will likely result in dilution to current shareholders and could be at prices below the true value of common stock.

Worse than expectedThe company faces substantial doubt about its ability to continue as a going concern due to significant debt maturities in late 2025 and mid-2026.The company is in default of a fixed asset acquisition covenant and a Fixed Charge Coverage Ratio covenant as of June 30, 2025, indicating financial strain.Year-to-date net sales decreased by 12.6%, and the net loss for the nine months ended September 30, 2025, widened significantly to $1.45 million from $812,000 in the prior year.Cash flow from operating activities turned negative, using $754,000 for the nine months, compared to generating $508,000 in the prior year, primarily due to a large increase in inventory.Working capital decreased by 63.3%, indicating a deterioration in short-term liquidity.

Summary

Net sales for the three months ended September 30, 2025, decreased by 17.9% to $10.3 million, while net sales for the nine months decreased by 12.6% to $35.1 million compared to the prior year periods.
Gross profit percentage increased to 22.3% for Q3 2025 (from 15.5% in Q3 2024) and to 18.1% for the nine months (from 16.2% in 2024), driven by product mix changes and cost reductions.
The net loss for Q3 2025 significantly narrowed to $44,000 from $404,000 in Q3 2024, but the net loss for the nine months widened to $1.45 million from $812,000 in the prior year.
Operating expenses increased by 5.6% in Q3 and 14.3% for the nine months, primarily due to higher stock compensation, professional fees, and IT system improvements.
Cash used in operating activities for the nine months ended September 30, 2025, was $754,000, a shift from $508,000 generated in the prior year, mainly due to a significant increase in inventory.
Total debt under the Current Credit Facility and Related Party Subordinated Notes approximates $26.8 million as of September 30, 2025, all classified as current liabilities.
The company is in default of a fixed asset acquisition covenant (exceeding $2.5 million limit) and a required minimum Fixed Charge Coverage Ratio (FCCR) of 1.05x as of June 30, 2025 (achieved 0.76x), though it met the 1.25x FCCR for September 30, 2025.
Total unfilled contract values, including backlog and potential funded orders against Long-Term Agreements, amounted to $269.0 million as of September 30, 2025, with backlog at $131.8 million.
The company raised $4.87 million in gross proceeds through an At The Market (ATM) Offering during the nine months ended September 30, 2025, with $3.93 million restricted for the Current Credit Facility lender.

Sentiment

Score: 3

Explanation: The sentiment is low due to significant going concern risk, multiple covenant defaults, declining year-to-date sales, and negative operating cash flow. While Q3 net loss improved and gross margins increased, the overarching debt maturity and liquidity challenges present a critical situation. The strong backlog offers future potential but is delayed, and current financial health is precarious.

Positives

Gross profit percentage improved significantly to 22.3% in Q3 2025 from 15.5% in Q3 2024, and to 18.1% for the nine months from 16.2% in the prior year, attributed to product mix and cost reductions.
Net loss for the three months ended September 30, 2025, substantially decreased to $44,000 from $404,000 in the same period last year.
Operating income for Q3 2025 increased to $316,000 from $67,000 in Q3 2024.
Total unfilled contract values, including backlog, reached $269.0 million as of September 30, 2025, providing a solid foundation for future growth.
Backlog increased to $131.8 million as of September 30, 2025, from $128.5 million at June 30, 2025.
Successfully raised $4.87 million in gross proceeds through an At The Market (ATM) Offering during the nine months ended September 30, 2025, enhancing liquidity.
The company was in compliance with its minimum Fixed Coverage Charge Ratio (FCCR) of 1.25x on a rolling 12-month basis as of September 30, 2025.
Interest expense decreased by 3.3% in Q3 and 4.5% for the nine months, partly due to lower subordinated debt levels and a reduced average interest rate on the Current Credit Facility.

Negatives

Substantial doubt exists about the company's ability to continue as a going concern due to the Current Credit Facility expiring on December 30, 2025, and Related Party Subordinated Notes maturing on June 30, 2026.
Net sales decreased by 17.9% in Q3 2025 and 12.6% for the nine months ended September 30, 2025, primarily due to timing and changes in product mix.
Net loss for the nine months ended September 30, 2025, increased to $1.45 million from $812,000 in the prior year.
Cash used in operating activities for the nine months ended September 30, 2025, was $754,000, a significant decline from $508,000 generated in the prior year, mainly due to a $5.6 million increase in inventory.
Working capital decreased by 63.3% to $4.32 million as of September 30, 2025, from $11.78 million at December 31, 2024.
The company is in default of the fixed asset acquisition covenant, having exceeded the $2.5 million limit for fiscal 2025.
A waiver has not yet been obtained for the default of a required minimum FCCR of 1.05x as of June 30, 2025, where the company only attained a ratio of 0.76x.
Operating expenses as a percentage of net sales increased to 19.2% in Q3 2025 (from 14.9% in Q3 2024) and to 19.3% for the nine months (from 14.8% in 2024).
The company has temporarily paused all equity raising activity while evaluating its capital structure, despite ongoing liquidity needs.

Risks

Substantial doubt about the company's ability to continue as a going concern due to the Current Credit Facility expiring on December 30, 2025, and Related Party Subordinated Notes maturing on June 30, 2026.
Inability to reach agreements with existing lenders or secure alternative financing for refinancing or extension of debt obligations.
The Current Credit Facility lender could exercise rights due to covenant defaults, such as increasing interest rates, refusing revolving loans, or retaining funds in the collection account, which would adversely impact operations.
Extended lead times for raw material procurement and complex manufacturing processes are expected to delay revenue acceleration until early 2026.
Reliance on sole-source suppliers for raw materials or parts, posing a severe risk if any supplier goes out of business or cannot provide parts.
Significant exposure to changes in the U.S. defense budget, which could materially impact demand for military aviation products.
Demand for commercial aviation products may be reduced if general economic conditions deteriorate.
A material weakness in internal controls over financial reporting related to IT systems has not yet been remediated, potentially affecting the ability to record, process, summarize, and report financial information reliably.
Potential dilution to current shareholders from future equity or convertible debt issuances, or more restrictive covenants from additional borrowings.
The state of capital markets may be adversely impacted by global events (public health crises, conflicts, banking crises, inflation, tariffs, geopolitical shifts), affecting the ability to raise funds.

Future Outlook

The company anticipates that revenue acceleration will be delayed until early 2026 due to extended lead times for raw material procurement and the complexity of manufacturing processes. Management believes it has sufficient liquidity for the next twelve months, contingent on its ability to refinance or extend its Current Credit Facility and Related Party Notes. The company is actively engaged in discussions with lenders and may explore options to raise additional capital, which could result in dilution or more restrictive covenants.

Management Comments

Management remains focused on enhancing profitability and improving cash flows through cost reductions, margin improvements, and long-term revenue growth.
In the third quarter of 2025, the Company initiated cost-saving measures, including a workforce reduction, to better align operating expenses with anticipated production volumes.
Although navigating the current business landscape remains challenging and it is difficult to predict period-to-period financial performance, based on the amounts recently raised pursuant to our ATM, our current revenue visibility and the strength of our backlog, we believe we have sufficient liquidity to meet our financial obligations for the next twelve months.
Our ability to meet financial obligations is dependent upon our ability to continue to borrow under our Current Credit Facility and ultimately extend the maturity dates of the Current Credit Facility and our Related Party Notes.

Industry Context

Air Industries Group operates in the highly specialized aerospace and defense sector, serving as a precision component manufacturer for major prime contractors. Its products are critical for U.S. military aviation programs (e.g., F-18, F-35, Black Hawk) and commercial aviation (e.g., GTF Engines). The industry is characterized by long lead times, complex manufacturing, and a reliance on government defense budgets and commercial air travel demand. The company's strategic investments in capital equipment and process improvements aim to enhance competitiveness in a market facing skilled worker shortages. Its position as a sole or single supplier for certain parts highlights its specialized capabilities but also exposes it to supplier risks.

Comparison to Industry Standards

The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. However, the company's focus on precision components for mission-critical aerospace and defense applications suggests it operates in a segment where quality and reliability are paramount, aligning with high industry standards for these attributes.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Equity Incentive Plan Amendment	Shareholders approved an amendment to the 2022 Equity Incentive Plan in June 2025, increasing the number of authorized shares by 250,000, from 650,000 to 900,000 shares.	2025-06-30	Increases the pool of shares available for stock-based compensation, potentially impacting future dilution but also providing incentives for employees and directors.

Legal Proceedings

Ongoing lawsuit with Contract Pharmacal Corp. regarding an alleged sublease violation, with damages reduced to $700,000. The company continues to dispute the claims, and the Appellate Division upheld the lower court's denial of Contract Pharmacal's motions. No significant developments are anticipated over the next twelve months.

Related Party Transactions

The company has outstanding Subordinated Notes Payable totaling $4,871,000 as of September 30, 2025, with Michael Taglich (Director), Robert Taglich (Director), and Taglich Brothers, Inc. (co-founded by the Taglichs).
During the nine months ended September 30, 2025, the company paid $1,291,000 in principal payments on these Related Party Notes, with $1,050,000 paid to Michael Taglich and $241,000 to Taglich Brothers, Inc.
Interest expense on related party subordinated notes payable was $86,000 for Q3 2025 and $271,000 for the nine months ended September 30, 2025.
Approximately $4,321,000 of these notes are convertible into common stock at $15.00 or $9.30 per share, while $550,000 is not convertible.

Stakeholder Impact

**Shareholders:** Face significant dilution risk from potential future equity raises and uncertainty regarding the company's going concern status. The stock price could be negatively impacted by the financial challenges and covenant defaults.
**Employees:** Workforce reductions have been initiated in Q3 2025, indicating potential job insecurity. Stock-based compensation is a notable component of operating expenses.
**Lenders (Webster Bank):** The Current Credit Facility lender faces increased risk due to covenant defaults and the upcoming maturity. They have secured additional collateral ($3.93 million restricted cash) but could exercise further remedies.
**Related Party Lenders (Taglichs, Taglich Brothers):** Their subordinated notes are also maturing soon and are subordinate to the Current Credit Facility, making their repayment dependent on the primary lender's actions.
**Customers (Aerospace & Defense Contractors):** Potential for supply chain disruption if the company's financial difficulties impact its ability to operate or expand, though the strong backlog suggests ongoing demand.
**Suppliers:** Sole-source suppliers face risks if the company's financial health deteriorates, potentially impacting their business relationships.

Next Steps

Actively engage in constructive discussions with all lenders regarding potential refinancing or extension of the Current Credit Facility (due December 30, 2025) and Related Party Subordinated Notes (due June 30, 2026).
Continue to implement cost-saving measures, including potential additional workforce reductions, to enhance profitability and improve cash flows.
Address and remediate the material weakness in internal controls over financial reporting related to IT systems.
Invest approximately an additional $350,000 in capital equipment during the remainder of fiscal 2025, principally for tooling required to produce product.
Explore options to raise additional capital or borrow additional funds on favorable terms, subject to lender consent and potential shareholder dilution.

Key Dates

Date	Description
2018-10-02	Contract Pharmacal Corp. commenced a lawsuit against the company relating to a sublease.
2019-12-31	Company entered into a credit facility (Current Credit Facility) with Webster Bank.
2021-07-08	Court denied Contract Pharmacal's motion for summary judgment and to add an additional cause of action, and granted its motion to reduce damages claim to $700,000.
2021-11-30	Court denied Contract Pharmacal's motion to reargue its original motion.
2022-03-10	Contract Pharmacal filed an appeal of the Court's decision with the Appellate Division of the State of New York.
2023-08-16	Company entered into a financing agreement (Solar Credit Facility) with CT Green Bank.
2023-12-15	Effective date for ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures for fiscal years beginning after this date.
2024-05-31	Company entered into a Seventh Amendment to the Current Credit Facility, waiving a previous default and revising financial covenants.
2024-09-30	Shareholders approved an amendment to the 2022 Equity Incentive Plan to increase authorized shares by 300,000 to 650,000.
2024-10-01	Cumulative advances of $934,000 and accrued interest of $36,000 under the Solar Credit Facility converted to a 20-year term loan of $970,000.
2024-11-30	Effective date for ASU 2024-03, Disaggregation of Income Statement Expenses, for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027.
2024-12-19	Registration Statement on Form S-3 for ATM offering declared effective.
2024-12-31	Company was in full compliance with Current Credit Facility covenants.
2025-01-30	Company entered into an Eighth Amendment to the Current Credit Facility, providing an additional $1.64 million Term Loan for equipment acquisition and revising financial covenants.
2025-06-30	Shareholders approved an amendment to the 2022 Equity Incentive Plan to increase authorized shares by 250,000 to 900,000.
2025-07-01	First semi-annual payment on Solar Credit Facility term loan due (interest only).
2025-07-31	Effective date for ASU 2025-05, Financial Instruments – Credit Losses (Topic326): Measurement of Credit Loss for Accounts Receivable and Contract Assets, for annual reporting periods beginning after December 15, 2025, and interim periods within those annual periods.
2025-09-10	Company entered into a Ninth Amendment to the Current Credit Facility, agreeing to maintain $3.93 million of ATM proceeds in a restricted interest-bearing account as additional security.
2025-09-30	End of the quarterly reporting period.
2025-10-31	Company issued 3,823 shares of common stock in payment of directors fees totaling $12,000.
2025-11-12	Date as of which 4,775,777 shares of common stock were outstanding.
2025-11-14	Filing date of the Form 10-Q.
2025-12-30	Maturity date of the Current Credit Facility with Webster Bank.
2026-01-01	Subsequent semi-annual payments on Solar Credit Facility term loan will include both principal and interest.
2026-06-30	Maturity date of the Related Party Subordinated Notes.
2026-07-20	Final payment due on the loan payable for a financed delivery vehicle.

Recommendation

strong sell

The company faces substantial doubt about its ability to continue as a going concern, with significant debt maturities looming in late 2025 and mid-2026. It is currently in default of multiple loan covenants, which grants its primary lender the right to demand immediate repayment or impose harsher terms. While Q3 showed a reduced net loss and improved gross margins, year-to-date performance is worse, with declining sales and negative operating cash flow. The large increase in inventory and significant reduction in working capital further highlight liquidity issues. Despite a strong backlog, revenue acceleration is delayed, and the company has paused equity raising efforts amidst critical refinancing discussions. The material weakness in internal controls adds another layer of operational risk. Given the severe liquidity crunch, covenant breaches, and the uncertainty of debt refinancing, the risk of significant capital loss is extremely high, making it a strong sell.

Keywords

aerospace, defense, manufacturing, precision components, SEC filing, 10-Q, financial results, debt maturity, going concern, covenant default, backlog, capital raise, liquidity, risk factors, military aviation, commercial aviation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.